CPC C07K 16/2803 (2013.01) [A61K 39/39541 (2013.01); A61K 45/06 (2013.01); C12P 21/02 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] | 21 Claims |
1. A method of treating cancer, or alleviating a symptom of cancer, the method comprising administering a monoclonal anti-CD47 antibody which specifically binds to human CD47 to a subject in need thereof, wherein the anti-CD47 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence:
| ||||||||
wherein X1 is M or there is no amino acid at position X1, X2 is M or V, X3 is P, X4 is S or A, X5 is A or G, X6 is F or L, X7 is G, X8 is I or M, X9 is R or T, X10 is R or T, X11 is T, X12 is R, X13 is E or D, and X14 is V;
wherein the anti-CD47 antibody comprises a light chain variable region (VL) comprising CDR1, CDR2, and CDR3 comprising amino acid sequences KASQDIHRYLS (SEQ ID NO:17), RANRLVS (SEQ ID NO: 18), and LQYDEFPYT (SEQ ID NO:19), respectively.
|